Logo image of ETTX

Entasis Therapeutics Holdings Inc (ETTX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ETTX - US2936141033 - Common Stock

2.19
-0.01 (-0.45%)
Last: 7/8/2022, 8:00:02 PM
Fundamental Rating

2

Overall ETTX gets a fundamental rating of 2 out of 10. We evaluated ETTX against 530 industry peers in the Biotechnology industry. The financial health of ETTX is average, but there are quite some concerns on its profitability. ETTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ETTX has reported negative net income.
ETTX Yearly Net Income VS EBIT VS OCF VS FCFETTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 -10M -20M -30M -40M -50M

1.2 Ratios

Industry RankSector Rank
ROA -117.26%
ROE N/A
ROIC -125.57%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ETTX Yearly ROA, ROE, ROICETTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ETTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ETTX Yearly Profit, Operating, Gross MarginsETTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 -200 -400 -600

More info and screens

5

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ETTX is destroying value.
The number of shares outstanding for ETTX has been increased compared to 1 year ago.
There is no outstanding debt for ETTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ETTX Yearly Shares OutstandingETTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M
ETTX Yearly Total Debt VS Total AssetsETTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -8.99, we must say that ETTX is in the distress zone and has some risk of bankruptcy.
There is no outstanding debt for ETTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.99
ROIC/WACC-13.14
WACC9.55%
ETTX Yearly LT Debt VS Equity VS FCFETTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

ETTX has a Current Ratio of 1.65. This is a normal value and indicates that ETTX is financially healthy and should not expect problems in meeting its short term obligations.
A Quick Ratio of 1.65 indicates that ETTX should not have too much problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 1.65
Quick Ratio 1.65
ETTX Yearly Current Assets VS Current LiabilitesETTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

ETTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 28.66%, which is quite impressive.
EPS 1Y (TTM)28.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.34%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ETTX will show a small growth in Earnings Per Share. The EPS will grow by 2.06% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-11.98%
EPS Next 2Y-3.74%
EPS Next 3Y12.27%
EPS Next 5Y2.06%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ETTX Yearly Revenue VS EstimatesETTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2023 2024 2025 2026 50M 100M 150M 200M
ETTX Yearly EPS VS EstimatesETTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ETTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ETTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ETTX Price Earnings VS Forward Price EarningsETTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -1.28
ETTX Per share dataETTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

ETTX's earnings are expected to grow with 12.27% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.74%
EPS Next 3Y12.27%

More info and screens

0

5. Dividend

5.1 Amount

ETTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Entasis Therapeutics Holdings Inc

NASDAQ:ETTX (7/8/2022, 8:00:02 PM)

2.19

-0.01 (-0.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-27 2022-04-27/bmo
Earnings (Next)08-09 2022-08-09
Inst Owners2.61%
Inst Owner Change-82.85%
Ins Owners49.22%
Ins Owner Change0%
Market Cap104.80M
Revenue(TTM)N/A
Net Income(TTM)-51.70M
Analysts47.5
Price Target2.04 (-6.85%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.29
P/tB N/A
EV/EBITDA -1.28
EPS(TTM)-1.12
EYN/A
EPS(NY)-1.17
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS0.35
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -117.26%
ROE N/A
ROCE N/A
ROIC -125.57%
ROICexc N/A
ROICexgc -125.57%
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.65
Quick Ratio 1.65
Altman-Z -8.99
F-Score3
WACC9.55%
ROIC/WACC-13.14
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.34%
EPS Next Y-11.98%
EPS Next 2Y-3.74%
EPS Next 3Y12.27%
EPS Next 5Y2.06%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

Entasis Therapeutics Holdings Inc / ETTX FAQ

What is the ChartMill fundamental rating of Entasis Therapeutics Holdings Inc (ETTX) stock?

ChartMill assigns a fundamental rating of 1 / 10 to ETTX.


What is the valuation status of Entasis Therapeutics Holdings Inc (ETTX) stock?

ChartMill assigns a valuation rating of 1 / 10 to Entasis Therapeutics Holdings Inc (ETTX). This can be considered as Overvalued.


Can you provide the profitability details for Entasis Therapeutics Holdings Inc?

Entasis Therapeutics Holdings Inc (ETTX) has a profitability rating of 1 / 10.